psalexa
logo

Retinitis Pigmentosa Therapeutics Pipeline Analysis, 2017

Retinitis Pigmentosa Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designations, Collaborations, and Other Developments

Published: November 2017
Report Code: LS11345
Available Format:
Pages: 121

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1 Overview

4.2 Key Drivers

4.3 Key Barriers

4.4 Retinitis pigmentosa Therapeutics Pipeline Analysis

4.4.1 Pipeline Analysis by Phase

4.4.2 Pipeline Analysis by Molecule Type

4.4.3 Pipeline Analysis by Route of Administration

4.4.4 Pipeline Analysis by Company

Chapter 5. Retinitis Pigmentosa Therapeutics Pipeline Analysis by Phase (2017)

5.1 Filed: Drug profiles

5.1.1 Pre-Clinical Study

5.1.2 Pre-Clinical Results

5.1.3 Clinical Trials

5.1.4 Clinical Results

5.1.5 Strategic Development

5.1.6 Designation

5.1.7 Grants

5.1.8 Patent

5.1.9 Technology

5.2 Phase III: Drug profiles

5.2.1 Pre-Clinical Study

5.2.2 Pre-Clinical Results

5.2.3 Clinical Trials

5.2.4 Clinical Results

5.2.5 Strategic Development

5.2.6 Designation

5.2.7 Grants

5.2.8 Patent

5.2.9 Technology

5.3 Phase II: Drug profiles

5.3.1 Pre-Clinical Study

5.3.2 Pre-Clinical Results

5.3.3 Clinical Trials

5.3.4 Clinical Results

5.3.5 Strategic Development

5.3.6 Designation

5.3.7 Grants

5.3.8 Patent

5.3.9 Technology

5.4 Phase I: Drug profiles

5.4.1 Pre-Clinical Study

5.4.2 Pre-Clinical Results

5.4.3 Clinical Trials

5.4.4 Clinical Results

5.4.5 Strategic Development

5.4.6 Designation

5.4.7 Grants

5.4.8 Patent

5.4.9 Technology

5.5 Pre-Clinical: Drug profiles

5.5.1 Pre-Clinical Study

5.5.2 Pre-Clinical Results

5.5.3 Strategic Development

5.5.4 Designation

5.5.5 Grants

5.5.6 Patent

5.5.7 Technology

5.6 Discovery: Drug profiles

5.6.1 Strategic Development

5.6.2 Designation

5.6.3 Grants

5.6.4 Patent

5.6.5 Technology

5.7 Unknown: Drug profiles

5.7.1 Pre-Clinical Study

5.7.2 Pre-Clinical Results

5.7.3 Clinical Trials

5.7.4 Clinical Results

5.7.5 Strategic Development

5.7.6 Designation

5.7.7 Grants

5.7.8 Patent

5.7.9 Technology

Chapter 6. Clinical Trials Analysis

6.1 Clinical Trials by Region for Retinitis Pigmentosa Therapeutics Pipeline

6.2 Clinical Trials by Trial Status for Retinitis Pigmentosa Therapeutics Pipeline

Chapter 7. Competitive Landscape

7.1 Key Players Benchmarking for Retinitis Pigmentosa Therapeutics Pipeline

7.2 SWOT Analysis Retinitis Pigmentosa Therapeutics Pipeline

7.2.1 Strengths

7.2.2 Weaknesses

7.2.3 Opportunities

7.2.4 Threats

Chapter 8. Company Profiles

8.1 Business Overview

8.2 Product and Service Offerings

Chapter 9. Appendix

9.1 Abbreviations

9.2 Related Reports

 

LIST OF TABLES

 

PIPELINE ANALYSIS OF RETINITIS PIGMENTOSA THERAPEUTICS, BY COMPANY (2017)

DESCRIPTION OF PHASE FILED DRUG CANDIDATES

CLINICAL TRIALS OF FILED DRUG CANDIDATES

DESCRIPTION OF PHASE III DRUG CANDIDATES

CLINICAL TRIALS OF PHASE III DRUG CANDIDATES

DESCRIPTION OF PHASE II DRUG CANDIDATES

CLINICAL TRIALS OF PHASE II DRUG CANDIDATES

DESCRIPTION OF PHASE I DRUG CANDIDATES

CLINICAL TRIALS OF PHASE I DRUG CANDIDATES

DESCRIPTION OF PRE-CLINICAL DRUG CANDIDATES

DESCRIPTION OF DISCOVERY DRUG CANDIDATES

DESCRIPTION OF UNKNOWN DRUG CANDIDATES

COMPANIES - AT A GLANCE

 

LIST OF FIGURES

 

RESEARCH METHODOLOGY

SPLIT OF PRIMARY AND SECONDARY RESEARCH

BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY INDUSTRY PARTICIPANT

BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY COMPANY TYPE

RETINITIS PIGMENTOSA THERAPEUTICS DRUG CANDIDATES UNDER DEVELOPMENT (2017)

RETINITIS PIGMENTOSA PIPELINE SPLIT, BY MOLECULE TYPE (2017)

RETINITIS PIGMENTOSA THERAPEUTICS PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2017)

BREAKDOWN OF CLINICAL TRIALS, BY REGION

BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS

KEY PLAYERS BENCHMARKING

SWOT ANALYSIS

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 2500
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 3250
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry